Login to Your Account

Clinic roundup

Monday, May 12, 2014
Bind Therapeutics Inc., of Cambridge, Mass., reported in its first quarter earnings call that a pre-specified evaluation of patients enrolled in its phase II non-small-cell lung cancer (NSCLC) trial with KRAS mutations showed that, of the six patients with KRAS mutations treated with BIND-014, two demonstrated a confirmed partial response and two had durable stable disease, defined as lasting 12 weeks or longer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription